Evidence map›Paper›PMID 34881035›Full record

ArticleMolecular and clinical oncology2022

Investigation of EGFR mutations in non-small cell lung cancer usually undetectable by PCR methods.

Taisuke Matsubara, Eiji Nakajima, Haruka Namikawa, Shotaro Ono, Ikki Takada, Tatsuo Ohira, Yukio Morishita, Teruo Miyazaki, Kinya Furukawa, Norihiko Ikeda

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Taisuke MatsubaraDepartment of Surgery, Tokyo Medical University, Tokyo 160-0023, Japan.
Eiji NakajimaDepartment of Thoracic Surgery, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki 300-0395, Japan.
Haruka NamikawaDepartment of Surgery, Tokyo Medical University, Tokyo 160-0023, Japan.
Shotaro OnoDepartment of Thoracic Surgery, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki 300-0395, Japan.
Ikki TakadaDepartment of Thoracic Surgery, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki 300-0395, Japan.
Tatsuo OhiraDepartment of Surgery, Tokyo Medical University, Tokyo 160-0023, Japan.
Yukio MorishitaDepartment of Diagnostic Pathology, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki 300-0395, Japan.
Teruo MiyazakiDepartment of Joint Research Center, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki 300-0395, Japan.
Kinya FurukawaDepartment of Thoracic Surgery, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki 300-0395, Japan.
Norihiko IkedaDepartment of Surgery, Tokyo Medical University, Tokyo 160-0023, Japan.
Tokyo Medical University Ibaraki Medical Center · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR) mutations are the most significant genomic drivers of non-small cell lung cancer (NSCLC) and determine the efficacy of EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. PCR methods are used clinically for the detection of EGFR mutations. The Scorpion Amplification Refractory Mutation System (Scorpion-ARMS) and the cobas

Indexed as

EGFR mutationLODnon-small cell lung cancerPCR methodTKI

Identifiers

PMID34881035
PMCPMC8637854
OpenAlexW3216832302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.